Earkart (544549)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let's begin with what I don't know. There is no book value, ROE, debt-equity ratio, or promoter holding disclosed. Graham would refuse to pay for a business he can't see. What I do see is a small medical equipment supplier at ₹149 with a market cap of ₹205 Cr. The trailing P/E of 37.81 is rich for a company whose sales fell 5.35% and profits collapsed 44.11%. A Piotroski score of 3 out of 9 reinforces that financial health is weak. The latest quarter, with sales of ₹22 Cr and net profit of ₹2 Cr, still shows a positive margin, but one quarter does not make a turnaround. ROCE of 45.13% is eye-catching, but with no debt or equity details, it may be a distorted metric from a thin capital base. I prefer predictable growth, moats, and decent returns on tangible capital. This has none of that visible. The zero dividend means I am not being paid to wait. At 37.8 times earnings, the market is already pricing in a strong recovery while the underlying business contracts. Buffett would say: 'Be fearful when others are greedy, and greedy when others are fearful.' Here, I am neither greedy nor fearful—I am confused, and confusion is not an investment thesis. For it to become attractive, Earkart must prove it can stabilize sales, rebuild profitability, and offer complete financials. Until then, this is a skip in my circle of competence.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer